PharmGKB summary: very important pharmacogene information for CYP1A2
- PMID: 21989077
- PMCID: PMC3346273
- DOI: 10.1097/FPC.0b013e32834c6efd
PharmGKB summary: very important pharmacogene information for CYP1A2
Erratum in
-
PharmGKB summary: very important pharmacogene information for CYP1A2: Erratum.Pharmacogenet Genomics. 2019 Nov;29(9):224. doi: 10.1097/FPC.0000000000000387. Pharmacogenet Genomics. 2019. PMID: 31568137 No abstract available.
References
-
- Ueda R, Iketaki H, Nagata K, Kimura S, Gonzalez FJ, Kusano K, et al. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol. 2006;69:1924–1930. - PubMed
-
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414–423. - PubMed
-
- Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093–1108. - PubMed
-
- Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002;12:473–478. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
